Related Experiment Video
Updated: Nov 2, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
CircPVT1 promotes proliferation of lung squamous cell carcinoma by binding to miR-30d/e
Jie Shi1, Xin Lv1, Lizhong Zeng1
1Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, 157th Xiwu Road, Xi'an, 710000, People's Republic of China.
Background:
Circular RNAs (circRNAs) are a new type of extensive non-coding RNAs that regulate the activation and progression of different human diseases, including cancer. However, information on the underlying mechanisms and clinical significance of circRNAs in lung squamous cell carcinoma (LUSC) remains scant.
Methods:
The expression profile of RNAs in 8 LUSC tissues, and 9 healthy lung tissues were assayed using RNA sequencing (RNA-seq) techniques. Real-time quantitative polymerase chain reaction (qRT-PCR) was used to profile the expression of circPVT1 and its relationship with the prognosis of LUSC, i.e., survival analysis. Moreover, in vitro and in vivo experiments were performed to evaluate the impacts of circPVT1 on the growth of tumors. RNA pull-down tests, mass spectrometry, dual-luciferase reporter assessment, and RNA immune-precipitation tests were further conducted to interrogate the cross-talk between circPVT1, HuR, or miR-30d/e in LUSC.
Results:
Our data showed that circPVT1 was upregulated in LUSC tissues, serum, and cell lines. LUSC patients with higher circPVT1 expression exhibited shorter survival rates. The in vivo and in vitro data revealed that circPVT1 promotes the proliferation of LUSC cells. Additionally, mechanistic analysis showed that HuR regulated circPVT1. On the other hand, circPVT1 acted as a competing endogenous RNA (ceRNA) of miR-30d and miR-30e in alleviating the suppressive influences of miR-30d and miR-30e on its target cyclin F (CCNF).
Conclusion:
CircPVT1 promotes LUSC progression via HuR/circPVT1/miR-30d and miR-30e/CCNF cascade. Also, it acts as a novel diagnostic biomarker or treatment target of individuals diagnosed with LUSC.
Insights
Circular RNA PVT1 (circPVT1) promotes lung squamous cell carcinoma (LUSC) progression by interacting with HuR and acting as a ceRNA for miR-30d/e to regulate CCNF. CircPVT1 may serve as a diagnostic biomarker for LUSC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Circular RNAs (circRNAs) are emerging regulators in human diseases, including cancer.
- The role and mechanisms of circRNAs in lung squamous cell carcinoma (LUSC) are not well understood.
Purpose of the Study:
- To investigate the expression, function, and clinical significance of circPVT1 in LUSC.
- To elucidate the molecular mechanisms underlying circPVT1's role in LUSC progression.
Main Methods:
- RNA sequencing (RNA-seq) and qRT-PCR for expression profiling.
- In vitro and in vivo experiments to assess circPVT1's functional impact.
- Molecular assays including RNA pull-down, mass spectrometry, and dual-luciferase reporter assays to determine interactions.
Main Results:
- circPVT1 was significantly upregulated in LUSC tissues, serum, and cell lines.
- Higher circPVT1 expression correlated with poorer survival rates in LUSC patients.
- circPVT1 promotes LUSC cell proliferation and tumor growth by regulating the HuR/circPVT1/miR-30d/e/CCNF axis.
Conclusions:
- circPVT1 promotes LUSC progression through a complex regulatory cascade involving HuR and the ceRNA network of miR-30d/e and CCNF.
- circPVT1 represents a potential diagnostic biomarker and therapeutic target for LUSC.
Related Concept Videos
Abnormal Proliferation
MicroRNAs
MicroRNAs
Mitogens and the Cell Cycle
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

